title: Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling.
abstract: Calcineurin inhibitors (CNIs) are potent immunosuppressants with associated long-term nephrotoxicity mediated by tubular epithelial cell injury and arterial vasoconstriction. We hypothesized that CNI-induced renal injury is regulated by specific microRNAs (miRNAs). In this study, we found that 46 miRNAs were significantly altered in human proximal tubular epithelial cells (HPTECs) following exposure to cyclosporine A (CsA), particularly miR-21 (5.47 ± 0.47-fold versus vehicle, P = 0.002). This increase was accompanied by alterations in epithelial-mesenchymal transformation (EMT) markers including vimentin (2.80 ± 0.28-fold; P = 0.03), S100A4 (2.29 ± 0.29-fold; P = 0.04), and α-SMA (5.0 ± 0.31-fold; P = 0.03). Notably, transfection of HPTECs with miR-21 precursor also resulted in significant induction of EMT-associated genes, which were inhibited by a single-stranded nucleic acid inhibitor of miR-21. miR-21 induction resulted in a rapid increase of phosphorylated AKT and downregulation of PTEN. While CsA induces SMAD7 downregulation and TGF-β1 upregulation in HPTECs, such changes were independent of miR-21. Moreover, there was no effect on ERK phosphorylation. We confirmed these changes using a mouse model of CsA toxicity. Collectively, our results suggest that miR-21 mediates CsA nephrotoxicity via PTEN/AKT signaling pathway. Further exploration into the epigenetic response to CsA exposure may provide new therapeutic targets to ameliorate CsA nephrotoxicity.
authors.affiliation: Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Jianguo
authors.initials: J
authors.lastname: Chen
authors.forename: Anna
authors.initials: A
authors.lastname: Zmijewska
authors.forename: Degui
authors.initials: D
authors.lastname: Zhi
authors.forename: Roslyn B
authors.initials: RB
authors.lastname: Mannon
mesh_terms: D064591:Allografts; D000818:Animals; D065095:Calcineurin Inhibitors / Q000009:adverse effects*; D002478:Cells, Cultured; D016572:Cyclosporine / Q000009:adverse effects*; D058750:Epithelial-Mesenchymal Transition; D048049:Extracellular Signal-Regulated MAP Kinases / Q000502:physiology; D005355:Fibrosis; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D051379:Mice; D035683:MicroRNAs / Q000502:physiology*; D051059:PTEN Phosphohydrolase / Q000502:physiology; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology*; D015398:Signal Transduction; D051906:Smad7 Protein / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000502:physiology
chemical_list: D065095:Calcineurin Inhibitors; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D051906:Smad7 Protein; D016212:Transforming Growth Factor beta; D016572:Cyclosporine; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D051059:PTEN Phosphohydrolase
keywords: cyclosporine; fibrosis; microRNA; nephrotoxicity; signaling; transplantation